V.I. Technologies
This article was originally published in The Gray Sheet
Executive Summary
Health Care Financing Administration assigns a HCPCS product code and reimbursement rate for the company's PLAS+SD transfusion plasma product. The system utilizes a solvent detergent process to inactivate deadly viruses such as HIV, hepatitis C and hepatitis B in plasma. Effective July 1, the rate has been set at $169, representing a $60 premium over the reimbursement rate for untreated fresh frozen plasma. According to the company, approximately 50-60% of procedures are done on Medicare patients and sales are expected to benefit from the new code